

## Clinical Policy: Talimogene Laherepvec (Imlygic)

Reference Number: ERX.SPA.440

Effective Date: 09.01.21

Last Review Date: 08.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

### Description

Talimogene laherepvec (Imlygic<sup>™</sup>) is genetically modified oncolytic viral therapy.

### FDA Approved Indication(s)

Imlygic is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitation(s) of use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

*Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.*

It is the policy of health plans affiliated with Envolve Pharmacy Solutions<sup>™</sup> that Imlygic is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Melanoma (must meet all):

1. Diagnosis of unresectable or limited resectable melanoma;
2. Prescribed by or in consultation with an oncologist;
3. Age  $\geq$  18 years;
4. Administered as single agent;
5. Documentation of both of the following (a and b):
  - a. Lesions are cutaneous, subcutaneous, or nodal;
  - b. Quantity and sizes of lesions;
6. Request meets one of the following (a, b, or c):\*
  - a. For initial dose: Dose does not exceed 4 mL of  $10^6$  plaque-forming units (PFU)/mL (see *Appendix E*);
  - b. For all subsequent doses (starting 3 weeks after initial dose): Dose does not exceed 4 mL of  $10^8$  PFU/mL every 2 weeks (see *Appendix E*);
  - c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6 months**

##### B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

## II. Continued Therapy

### A. Melanoma (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or documentation supports that member is currently receiving Imlygic for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Documentation supports quantity and sizes of lesions that remain to be treated;
4. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 4 mL of  $10^8$  PFU/mL every 2 weeks (see Appendix E);
  - b. New dose is supported by practice guideline or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

\*Prescribed regimen must be FDA-approved or recommended by NCCN

**Approval duration: 12 months**

### B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

## III. Diagnoses/Indications for which coverage is NOT authorized:

- ### A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

## IV. Appendices/General Information

### Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

PFU: plaque-forming units

### Appendix B: Therapeutic Alternatives

Not applicable

### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): immunocompromised patients, pregnancy
- Boxed warning(s): none

### Appendix D: Determination of Imlygic Injection Volume Based on Lesion Size

Lesion Size (longest dimension)	Injection Volume
> 5 cm	up to 4 mL
> 2.5 cm to 5 cm	up to 2 mL
> 1.5 cm to 2.5 cm	up to 1 mL
> 0.5 cm to 1.5 cm	up to 0.5 mL
≤ 0.5 cm	up to 0.1 mL

When lesions are clustered together, they should be injected together as a single lesion according to this table.

## V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Melanoma	Recommended starting dose for injection into cutaneous, subcutaneous, and/or nodal lesions is up to 4 mL at a concentration of $10^6$ (1 million) PFU/mL, followed by up to 4 mL of $10^8$ (100 million) PFU/mL administered 3 weeks later; thereafter, subsequent doses of up to 4 mL of $10^8$ PFU/mL are administered every 2 weeks	See regimen

**VI. Product Availability**

Single-use vials: 10<sup>6</sup> (1 million) PFU/mL, 10<sup>8</sup> (100 million) PFU/mL

**VII. References**

1. Imlygic Prescribing Information. Thousand Oaks, CA: Amgen; October 2019. Available at: [https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/imlygic/imlygic\\_pi.pdf](https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/imlygic/imlygic_pi.pdf). Accessed May 25, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [https://www.nccn.org/professionals/drug\\_compendium/content/](https://www.nccn.org/professionals/drug_compendium/content/). Accessed May 25, 2021.
3. National Comprehensive Cancer Network. Cutaneous Melanoma Version 02.2021. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf). Accessed May 25, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	06.01.21	08.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2021 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.